Forty patients with stage IIIB or IV NSCLC were randomized to receive either a biweekly regimen of GC -LSB- gemcitabine ( @,@ mg/m ( @ ) on days @ and @ ) and carboplatin ( area under the concentration-time curve , AUC = @ on days @ and @ ) -RSB- every @ days or a standard regimen of GC -LSB- gemcitabine ( @,@ mg/m ( @ ) on days @ and @ ) and carboplatin ( AUC = @ on day @ ) -RSB- every @ days .